EU/3/19/2143: Orphan designation for the treatment of small cell lung cancer

Lurbinectedin

Table of contents

Overview

On 26 February 2019, orphan designation (EU/3/19/2143) was granted by the European Commission to Pharma Mar S.A., Spain, for lurbinectedin for the treatment of small cell lung cancer.

Key facts

Active substance
Lurbinectedin
Intended use
Treatment of small cell lung cancer
Orphan designation status
Positive
EU designation number
EU/3/19/2143
Date of designation
26/02/2019
Sponsor

Pharma Mar S.A.
Avda. de los Reyes, 1 
Pol. Ind. La Mina 
28770 Colmenar Viejo 
Madrid 
Spain
Tel. + 34 9182 34553
E-mail: abirigaray@pharmamar.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating
Average
2 ratings
1 rating
1 rating